CD4 and AIDS: The INSIGHT-START study, for example, found that early ART (initiation at CD4 >500 cells/mm3) reduced the risk of AIDS-related events, non-AIDS related events, and all-cause mortality compared to late ART (initiation at CD4 <350 cells/mm3) by 57% [95% CI: 38–70%][5].